Skip to main content
main-content
Top

09-14-2016 | Retinopathy | Article

Vision related quality of life in patients with type 2 diabetes in the EUROCONDOR trial

Journal: Endocrine

Authors: Marina Trento, Olga Durando, Sonia Lavecchia, Lorena Charrier, Franco Cavallo, Miguel Angelo Costa, Cristina Hernández, Rafael Simó, Massimo Porta, for the EUROCONDOR trial investigators

Publisher: Springer US

share
SHARE

Abstract

To evaluate vision related quality of life in the patients enrolled in The European Consortium for the Early Treatment of Diabetic Retinopathy, a clinical trial on prevention of diabetic retinopathy. Four-hundred-forty-nine patients, 153 women, with type 2 Diabetes and no or mild diabetic retinopathy were enrolled in a 2-year multicenter randomized controlled trial. The 25-item National Eye Institute Visual Functioning Questionnaire was used to explore 12 subscales of vision related quality of life. The patients were 62.8 ± 6.7 years old and had 11.1 ± 5.6 years known disease duration. Diabetic retinopathy was absent in 193 (43.0 %) and mild in 256 (57.0 %). Patients without diabetic retinopathy were older, had shorter diabetes duration and used less insulin and glucose-lowering agents but did not differ by gender, best corrected visual acuity or any subscale, except vision specific mental health and vision specific role difficulties. Patients with reduced retinal thickness at the ganglion cell layer (n = 36) did not differ for diabetic retinopathy but were older, had lower best corrected visual acuity and worse scores for ocular pain, color vision and peripheral vision. On multivariable analysis, worse scores for general vision remained associated with reduced retinal thickness, diabetes duration and best corrected visual acuity, and scores for visual specific mental health with diabetic retinopathy and lower best corrected visual acuity. Visual specific role difficulties were only associated with reduced best corrected visual acuity. Scores for driving decreased among females, with worsening of Hemoglobin A1c and best corrected visual acuity. Color vision depended only on reduced retinal thickness, and peripheral vision on both reduced thickness and best corrected visual acuity. The National Eye Institute Visual Functioning Questionnaire could detect subtle changes in patients’ perception of visual function, despite absent/minimal diabetic retinopathy.
Literature
1.
E.L. Lamoureux, E.S. Tai, J. Thumboo et al., Impact of diabetic retinopathy on vision-specific function. Ophthalmology 117, 757–765 (2010) CrossRef
2.
E.K. Fenwick, K. Pesudovs, G. Rees et al., The impact of diabetic retinopathy: understanding the patient’s perspective. Br. J. Ophthalmol. 95, 774–782 (2011) CrossRef
3.
M. Finger, G. Fleckenstein, F. Holz et al., Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools. Qual. Life Res. 17, 559–574 (2008) CrossRef
4.
G. Rees, M.B. Sasongko, E.K. Fenwick et al., Impact of diabetic retinopathy on patients’ beliefs about diabetes. Clin. Exp. Optom. 95, 371–376 (2012) CrossRef
5.
R. Simó, C. Hernández, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br. J. Ophthalmol. 96, 1285–1290 (2012) CrossRef
6.
K.J. Hellgren, E. Agardh, B. Bengtsson, Progression of early retinal dysfunction in diabetes over time: results of a long-term prospective clinical study. Diabetes 63, 3104–3111 (2014) CrossRef
7.
C. Hernández, O. Simó-Servat, R. Simó, Somatostatin and diabetic retinopathy: current concepts and new therapeutic perspectives. Endocrine 46, 209–214 (2014) CrossRef
8.
U. Frydkjaer-Olsen, R. Soegaard Hansen, R. Simó et al., Correlation between Retinal Vessel Calibre and Neurodegeneration in Patients with Type 2 Diabetes Mellitus in the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Ophth. Res. 56, 10–16 (2016) CrossRef
9.
S.S. Feman, T.C. Leonard-Martin, J.S. Andrews et al., A quantitative system to evaluate diabetic retinopathy from fundus photographs. Invest. Ophthalmol. Vis. Sci. 36, 174–181 (1995) PubMed
10.
C.M. Mangione, P.P. Lee, P.R. Gutierrez et al., National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item national eye institute visual function questionnaire. Arch. Ophthalmol. 119, 1050–1058 (2001) CrossRef
11.
A.T. Broman, B. Munoz, S.K. West et al., Psychometric properties of the 25-item NEI-VFQ in a Hispanic population: proyecto VER. Invest. Ophthalmol. Vis. Sci. 42, 606–613 (2001) PubMed
12.
G.C. Rossi, G. Milano, C. Tinelli, The Italian version of the 25-item National Eye Institute Visual Function Questionnaire: translation, validity and reliability. J. Glaucoma. 12, 213–220 (2003) CrossRef
13.
G.H. Franke, J. Esser, J. Reimer, N. Maehner, Vision targeted QoL under different degrees of visual impairment. R. Portug. Psicos. 4, 39–49 (2002)
14.
J.P. Nordmann, M. Viala, K. Sullivan, B. Arnould, G. Berdeaux, Psychometric Validation of the National Eye Institute Visual Function Questionnaire–25 (NEI VFQ-25) French version: in a population of patients treated for ocular hypertension and glaucoma. Pharmacoeconomics 22, 197–206 (2004) CrossRef
15.
M.S. Soresen, S. Andersen, G.O. Henningsen, T.L. Sørensen, Danish version of Visual Function Questionnaire-25 and its use in age-related macular degeneration. Danish medical bulletin 58, A4290 (2011)
16.
C. Hirneiss, C. Schmid-Tannwald, M. Kernt, A. Kampik, A.S. Neubauer, The NEI VFQ-25 vision-related quality of life and prevalence of eye disease in a working population. Graefes Arch. Clin. Exp. Ophthalmol. 248, 85–92 (2010) CrossRef
17.
A.E. Hipwell, J. Sturt, A. Lindenmeyer, I. Stratton, R. Gadsby, P. O’Hare, P.H. Scanlon, Attitudes, access and anguish: a qualitative interview study of staff and patients’ experiences of diabetic retinopathy screening. BMJ Open 4, e005498 (2014) CrossRef
18.
B.E. Wolff, M.A. Bearse Jr, M.E. Schneck et al., Color vision and neuroretinal function in diabetes. Doc. Ophthalmol. 130, 131–139 (2015) CrossRef
19.
M. Trento, L. Charrier, M. Salassa et al., Depression, anxiety and cognitive function in patients with type 2 diabetes: an 8-year prospective observational study. Acta Diabetol. 52, 1157–1166 (2015) CrossRef
20.
M. Trento, P. Passera, M. Trevisan et al., Quality of life, impaired vision and social role in people with diabetes: a multicenter observational study. Acta Diabetol. 50, 873–877 (2013) CrossRef
21.
L. Dandona, Dandona. Socioeconomic status and blindness. Br. J.Ophthalmol. 85, 1484–1488 (2001) CrossRef
22.
M. Marmot, Social determinants of health inequalities. Lancet 365, 1099–1104 (2005) CrossRef
23.
E.L. Lamoureux, E. Fenwick, J. Xie et al., Methodology and early findings of the Diabetes Management Project: a cohort study investigating the barriers to optimal diabetes care in diabetic patients with and without diabetic retinopathy. Clin. Experiment.Ophthalmol. 40, 73–82 (2012) CrossRef
24.
R.L. Thomas, F.D. Dunstan, S.D. Luzio et al., Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br. J. Ophthalmol. 99, 64–68 (2015) CrossRef